Pre-Surgery: 1. Subjects will be enrolled if they have confirmed HPV -positive HNSCCa. Tumor tissue sample must be available to perform immunological correlates prior to definitive surgery. 2. After providing informed consent and being deemed eligible, subjects will receive immunotherapy. Up to 2 doses may be administered approximately once every 3 weeks (± 3 days) prior to definitive surgery. 3. The number of pre -surgery immunotherapies (one vs. two injections ) will be based on the estimated time interval between pre -surgery evaluation and definitive surgery. Time to surgery according to standard practice is usually 2 - 4 weeks; however, this varies due to ordinary logistical considerations independent of a clinical trial. 4. Surgery will not be delayed to allow for immunotherapy. Post-Surgery: 1. Subjects will be seen approximately 2 weeks (± 7 days) post-surgery for follow up. 2. Subjects will undergo visual inspection t o document healing by surgeon approximately 4 weeks post-surgery. 3. Post-surgery immunotherapy will proceed only after approval of the surgeon. 8 Date: 8 April, 2016 v 2.1 INO-3112 UPCC # 39313 / HPV -005 Inovio Pharmaceuticals, Inc Clinical Protocol Post-Surgery (conti.) : 4. Subjects will receive up to 3 doses given 3 weeks (± 3 days) apart. A total of 4 doses (pre- and post- surgery) will be administered. 5. Immunotherapy will be administered prior to adjuvant chemotherapy and/or radiation that may be indicated. 6. Adjuvant therapy will not be delayed due to immunotherapy. 7. Subjects will be followed for tumor status as per institutional standard of care. Cohort II: Immunotherapy will start approximately 2-6 months after completion of definitive or adjuvant chemoradiation therapy in order to allow recovery from the treatment side effects of chemoradiation. INO-3112 will be delivered by IM injection followed by EP approximately once every 3 week s for a total of 4 doses. A minimum of 10 eligible subjects will be enrolled into this cohort.